Shigekatsu Maekawa

Dr. Shigekatsu Maekawa


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Cancer Cell
Verified
Journal Article
Closed access
YFYoichi Fujii
Yoichi Fujii
YSYusuke Sato
Yusuke Sato
HSHiromichi Suzuki
Hiromichi Suzuki
NKNobuyuki Kakiuchi
Nobuyuki Kakiuchi
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
SOSeishi Ogawa
Seishi Ogawa

25 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SMShigekatsu Maekawa
Shigekatsu Maekawa
RTRyo Takata
Ryo Takata
WOWataru Obara
Wataru Obara
The progression of prostate cancer (PCa) relies on the activation of the androgen receptor (AR) by androgens. Despite efforts to block this pathway through androgen deprivation therapy, resistance can occur through several mechanisms, including the abnormal activation of AR, resulting in castration-resistant PCa following the introduction of treatment. Mutations, amplifications, and splicing variants in AR-related genes have garnered attention in this regard. Furthermore, recent large-scale next-generation sequencing analysis has revealed the critical roles of AR and AR-related genes, as well as the DNA repair, PI3K, and cell cycle pathways, in the onset and progression of PCa. Moreover, research on epigenomics and microRNA has increasingly become popular; however, it has not translated into the development of effective therapeutic strategies. Additionally, treatments targeting homologous recombination repair mutations and the PI3K/Akt pathway have been developed and are increasingly accessible, and multiple clinical trials have investigated the efficacy of immune checkpoint inhibitors. In this comprehensive review, we outline the status of PCa research in genomics and briefly explore potential future developments in the field of epigenetic modifications and microRNAs.

1 January 2021 in Translational Oncology
Verified
Journal Article
Open access
RKRenpei Kato
Renpei Kato
NJNoriaki Jinnouchi
Noriaki Jinnouchi
TTTakashi Tuyukubo
Takashi Tuyukubo
DIDaiki Ikarashi
Daiki Ikarashi
TMTomohiko Matsuura
Tomohiko Matsuura
WOWataru Obara
Wataru Obara
• Multi-IF analysis was performed to identify novel prognostic biomarker for advanced RCC patients treated with anti-PD-1 therapy. • The strongest prognostic factor of response to anti-PD-1 therapy was identified as TIM3 expression on tumor cells. • Patients with TIM3-positive tumor cells showed significantly longer OS and PFS than those with TIM3-negative tumor cells.

15 November 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DIDaiki Ikarashi
Daiki Ikarashi
SKShigehisa Kitano
Shigehisa Kitano
TTTakashi Tsuyukubo
Takashi Tsuyukubo
KTKazumasa Takenouchi
Kazumasa Takenouchi
TNTakayuki Nakayama
Takayuki Nakayama
WOWataru Obara
Wataru Obara

1 September 2019 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
YHYutaka Hashimoto
Yutaka Hashimoto
MSMarisa Shiina
Marisa Shiina
PDPritha Dasgupta
Pritha Dasgupta
PKPriyanka Kulkarni
Priyanka Kulkarni
TKTaku Kato
Taku Kato
RDRajvir Dahiya
Rajvir Dahiya
Prostate cancer incidence and mortality rates are higher in African-American (AA) than in European-American (EA) men. The main objective of this study was to elucidate the role of miR-130b as a contributor to prostate cancer health disparity in AA patients. We also determined whether miR-130b is a prognostic biomarker and a new therapeutic candidate for AA prostate cancer. A comprehensive approach of using cell lines, tissue samples, and the TCGA database was employed. We performed a series of functional assays such as cell proliferation, migration, invasion, RT2-PCR array, qRT-PCR, cell cycle, luciferase reporter, immunoblot, and IHC. Various statistical approaches such as Kaplan–Meier, uni-, and multivariate analyses were utilized to determine the clinical significance of miR-130b. Our results showed that elevated levels of miR-130b correlated with race disparity and PSA levels/failure and acted as an independent prognostic biomarker for AA patients. Two tumor suppressor genes, CDKN1B and FHIT, were validated as direct functional targets of miR-130b. We also found race-specific cell-cycle pathway activation in AA patients with prostate cancer. Functionally, miR-130b inhibition reduced cell proliferation, colony formation, migration/invasion, and induced cell-cycle arrest. Inhibition of miR-130b modulated critical prostate cancer–related biological pathways in AA compared with EA prostate cancer patients. In conclusion, attenuation of miR-130b expression has tumor suppressor effects in AA prostate cancer. miR-130b is a significant contributor to prostate cancer racial disparity as its overexpression is a risk factor for poor prognosis in AA patients with prostate cancer. Thus, regulation of miR-130b may provide a novel therapeutic approach for the management of prostate cancer in AA patients.

1 December 2023 in International Journal of Urology
Verified
Journal Article
Closed access
YKYoichiro Kato
Yoichiro Kato
HAHidenori Akaihata
Hidenori Akaihata
KTKentaro Takezawa
Kentaro Takezawa
SMShigekatsu Maekawa
Shigekatsu Maekawa
KMKanako Matsuoka
Kanako Matsuoka
WOWataru Obara
Wataru Obara